U.S. lifts pause on Johnson & Johnson COVID-19 vaccine

Federal health agencies say they are ending their recommended pause on use of Johnson & Johnson's Janssen vaccine, following the vote of a panel of advisers to the Centers for Disease Control and Prevention on resuming the single-shot vaccine.

The Food and Drug Administration says they have revised their emergency use authorization for the vaccine to include a new warning about the "plausible" risk of rare but serious blood clots in adult women under 50. A panel of advisers to the Centers for Disease Control and Prevention voted earlier Friday to recommend resuming use of the Johnson & Johnson vaccine. The shots are expected to be accompanied by a new warning about an increased risk of rare but serious blood clots for adult women under 50.